Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What if there was no sellers? funny thing about small float stocks
At CTAD there is a good chance the Good Doctor announces FDA approval of at least the AD trial,,, hopefully Rett and PD...he has stated many times all starting in 2017... Nice headline coming out of CTAD .
and dude get with the times.
You all need to listen to the webcast... A great lead in to ctad... I am counting on a surprise... Like the FDA blessings
The crooks have scared them off.. thinking history will repeat itself... The good doctor learns from his mistakes..
You mean your short position..... Right?
Why do continue to ignore the Rett and PD trials? They will be 12 week duration.
Another breadcrumb.... this is what Anavex is going to do to the World of AD...
I hope you are very short this stock. GLTU
Welcome back... CTAD Anavex will present data to support the first precision approach to a PH 2/3 trial for a drug that is targeting the possible causes of AD.
I wonder what the reaction will be?
To me this is part of doing DD.
I will vouch for North...He has been around for quite some time. Has always been a great contributor to this board. BTW I bought the majority of my shares @ .17 pre split
Apples and oranges... you should know better...
Let's see whose presentation impresses more!
Any good performance saves the best for last. They want to keep the audience.
CTAD ... I believe 3:15... The PR we have been waiting for... IMHO
Not business days...
Last time it was 8 days. I think he is done ...CTAD
I do appreciate you and so many others trying to save ourselves from ourselves. But I, unlike some, like to take responsibility for my decisions and actions. Please continue your FUD it keeps us longs on our toes.
We have 28% of people in trials that responded well..they will guide in the selection of PH 2/3 participants. Sounds like a plan for success to me.
You have to admire the genius of the Good Doctor. Doing everything possible to design a PH 2/3 trial that will succeed..
They need to release the poster when presented.
"Paradigm shift in AD research" the media and market will notice... JMO
Listen to the webcast, it will tell all you need to know.
They will present data that gives the PH 2/3 a better than 50% chance of success. JMO
http://www.wsw.com/webcast/cc/avxl2/
When you are trying to find a needle in a haystack, it is that expensive. When you are using leading edge methods, it is not!
Shorts seem to be playing Russian Roulette.... or nobody wants to sell...
TRAPPED
You are missing the fact that we will use a precision medicine approach which will effectively "stack the deck in our favor"
Maybe the Good Doctor is not selling!
If you had any CNS disease and you were told you are among a group of people that the drug has been shown to be effective on... Would you sign up?
Oh, BTW the worst adverse even was dizziness.
Precision Medicine to the masses... and we have a versatile CNS drug.
2017 Posters
POSTERS
Alfonso Fasano, MD, PhD
University of Toronto, Toronto Western Hospital
Levodopa Versus Dopamine Agonist after Deep Brain Stimulation in Parkinson's
Veronica Francardo, PhD
Lund University
ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism
CTAD Nov.4th... stay tuned
From last quarter.... You believe or you don't!
“We are entering the second half of 2017 with our strongest balance sheet to date, which allows the Company to execute the Phase 2 clinical trial in Rett syndrome, for which ANAVEX™ 2-73 has been granted Orphan Drug Designation by the FDA, as well as the Phase 2/3 clinical trial in Alzheimer’s disease and the Phase 2 clinical trial in Parkinson’s disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex Life Sciences. “We look forward to initiating these placebo-controlled clinical trials. The respective trial designs are based on broad genomic and biomarker characterization, pharmacokinetic and pharmacodynamic modeling including data from patients in previous ANAVEX™ 2-73 trials, as well as preclinical translational science. To our knowledge, this is the first use of this approach in the design of clinical trials for Alzheimer’s disease, Parkinson’s disease and Rett syndrome, and marks a shift towards advancing implementation of precision medicine for these and other neurodegenerative and neurodevelopmental diseases.”
You need to do some DD on this subject and read what the Good Dr. has said about the upcoming trials... not so much speculation...
Excellent post... Should be stickied.
I am loving the old spirit of this board...
You implied it would do nasty things... this has not happened... it so prove it
Hasn't 273 been tested in Humans.
Yup. Lots of things happening before CTAD... The Good Doctors breadcrumbs should not be ignored.
Possible scenario…
Oct. 29
https://www.michaeljfox.org/?et_cid=980875&et_rid=262763965&et_lid=Watch+MJF+on+%26quot%3bCBS+Sunday+Morning%26quot%3bem_cid=
Oct. 30
https://www.michaeljfox.org/research/parkinsons-therapeutics-conference.html?navid=pd-therapeutics-conf
Oct. 31 thru Nov. 03
MJF announces start of Anavex 2-73 PH2 for PD
We will all have to wait and see.
I think CTAD will set all this up... and possibly show undeniable proof the drug has a better than 50% chance of being better than SOC.